United Therapeutics (NASDAQ:UTHR) CFO Sells $4,708,812.50 in Stock

Posted by Sarita Garza on Jun 26th, 2026

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CFO James Edgemond sold 8,750 shares of the business’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $538.15, for a total transaction of $4,708,812.50. Following the completion of the sale, the chief financial officer owned 18,876 shares in the company, valued at $10,158,119.40. This represents a 31.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

James Edgemond also recently made the following trade(s):

On Thursday, June 18th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $540.15, for a total transaction of $5,401,500.00.
On Monday, June 15th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $549.17, for a total transaction of $5,491,700.00.
On Thursday, June 11th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $549.29, for a total transaction of $5,492,900.00.
On Monday, June 8th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $547.50, for a total transaction of $5,475,000.00.
On Thursday, June 4th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $546.28, for a total transaction of $5,462,800.00.
On Monday, June 1st, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $547.87, for a total transaction of $5,478,700.00.
On Thursday, May 28th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $565.63, for a total value of $5,656,300.00.
On Tuesday, May 26th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $572.94, for a total value of $5,729,400.00.
On Thursday, May 21st, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $564.11, for a total value of $5,641,100.00.
On Monday, May 18th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $567.31, for a total value of $5,673,100.00.

United Therapeutics Price Performance

NASDAQ:UTHR opened at $543.39 on Friday. The firm has a market capitalization of $23.07 billion, a price-to-earnings ratio of 20.06, a PEG ratio of 1.81 and a beta of 0.57. The business has a 50 day simple moving average of $561.93 and a 200-day simple moving average of $525.46. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $609.35.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. During the same period in the prior year, the firm posted $6.63 EPS. The business’s revenue for the quarter was down 1.6% compared to the same quarter last year. As a group, analysts expect that United Therapeutics Corporation will post 26.49 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a research report on Thursday, June 11th. Royal Bank Of Canada lowered their target price on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Cantor Fitzgerald lifted their price target on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, March 12th. Morgan Stanley set a $516.00 price target on shares of United Therapeutics in a report on Thursday, May 7th. Finally, TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Eleven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $619.42.

Check Out Our Latest Analysis on United Therapeutics

Hedge Funds Weigh In On United Therapeutics

Several hedge funds have recently bought and sold shares of the business. Torren Management LLC purchased a new stake in United Therapeutics in the fourth quarter worth $26,000. Activest Wealth Management boosted its stake in shares of United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 56 shares during the period. WealthCollab LLC boosted its stake in shares of United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares during the period. Rakuten Securities Inc. grew its holdings in shares of United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 46 shares during the last quarter. Finally, Entrust Financial LLC bought a new position in shares of United Therapeutics in the fourth quarter worth about $31,000. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

(Get Free Report)

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.